Taysha Gene Therapies, Inc. (TSHA) Stock Analysis
A live, multi-source view of Taysha Gene Therapies, Inc. (TSHA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Sector: Healthcare · Industry: Biotechnology · United States · 99 employees · tayshagtx.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Taysha Gene Therapies, Inc. (TSHA) had a market capitalization of $1.82B (forward -12.1) and a beta of 1.17; the shares traded in a 52-week range of $2.71 – $7.30 (72.8% over the year).
- Market cap
- $1.82B
- Enterprise value
- $1.43B
- Forward P/E
- -12.1
- Price / book
- 7.59
- EPS (trailing)
- $-0.41
- EPS (forward)
- $-0.46
- Payout ratio
- 0.0%
- 52-week range
- $2.71 – $7.30
- 52-week change
- 72.8%
- Beta
- 1.17
- Average volume
- 3.1M
- Shares outstanding
- 325.8M
- Short % of float
- 14.57%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Taysha Gene Therapies, Inc. (TSHA) last closed at $5.16 (the last completed close before that scan).
Technicals at the scan: RSI 32 (neutral territory), price -11.8% versus its 20-day average, 20-day versus 50-day average spread -2.2%, MACD histogram -0.08.
Sentiment inputs: 67% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 81/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for TSHA in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
TSHA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Taysha Gene Therapies, Inc. (TSHA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell TSHA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.